2007
DOI: 10.3111/13696990701734415 View full text |Buy / Rent full text
|
|

Abstract: This modelling study aimed to evaluate the long-term cost effectiveness of four treatment strategies: early irbesartan; late irbesartan; amlodipine; and standard hypertensive treatment in patients with diabetes, hypertension and microalbuminuria in Taiwan. A Markov model was used to project costs and clinical outcomes over lifetimes.Early irbesartan (initiated in microalbuminuric patients) yielded the largest improvements in life expectancy (0.78 years) compared with standard treatment. Late irbesartan and aml… Show more

Help me understand this report

Search citation statements

Order By: Relevance
Select...
0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals